Whereas virus‐positive MCC harbors a low mutational burden and no recurring oncogenic alterations, virus‐negative MCC shows a ~ 100‐fold higher mutational load with recurrent inactivating mutations in RB1 and TP53 (Harms et al, 2015). This evidence concerns the gene RB1 and Merkel cell skin cancer.